Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E61.47 EPS (ttm)0.97 Insider Own0.11% Shs Outstand1.67B Perf Week-4.07%
Market Cap99.48B Forward P/E19.69 EPS next Y3.03 Insider Trans-5.95% Shs Float1.67B Perf Month-11.20%
Income1.62B PEG2.92 EPS next Q0.64 Inst Own73.90% Short Float1.31% Perf Quarter-8.63%
Sales16.56B P/S6.01 EPS this Y-19.20% Inst Trans0.26% Short Ratio3.38 Perf Half Y-5.04%
Book/sh9.03 P/B6.60 EPS next Y28.25% ROA5.00% Target Price73.90 Perf Year1.32%
Cash/sh3.24 P/C18.38 EPS next 5Y21.02% ROE10.70% 52W Range51.21 - 70.48 Perf YTD-13.32%
Dividend1.52 P/FCF- EPS past 5Y-11.50% ROI6.60% 52W High-15.40% Beta0.55
Dividend %2.55% Quick Ratio1.60 Sales past 5Y-3.20% Gross Margin76.80% 52W Low16.43% ATR1.92
Employees25000 Current Ratio1.80 Sales Q/Q0.70% Oper. Margin12.20% RSI (14)35.82 Volatility3.06% 3.32%
OptionableYes Debt/Eq0.48 EPS Q/Q-900.00% Profit Margin9.80% Rel Volume1.11 Prev Close59.63
ShortableYes LT Debt/Eq0.44 EarningsJan 28 BMO Payout152.60% Avg Volume6.46M Price59.63
Recom2.20 SMA20-3.95% SMA50-9.22% SMA200-7.28% Volume0 Change0.00%
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jun-04-13Reiterated Argus Buy $46 → $54
Apr-26-13Reiterated MKM Partners Sell $26 → $29
Apr-15-13Reiterated Barclays Equal Weight $33 → $42
Jan-25-13Reiterated UBS Neutral $34 → $36
Feb-08-16 05:53AM  Where is Ronald Reagan When You Need Him?
Feb-07-16 11:41AM  [$$] AstraZeneca cancer drug presents breakthrough at Financial Times
Feb-06-16 07:06AM  Eli Lilly and Co.s 4Q15 Business Segment Performance
Feb-05-16 12:47PM  U.S. FDA Approves Expanded Use of Bristol-Myers Squibbs Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Business Wire
Feb-04-16 03:40PM  Why Achillion Pharmaceuticals Shares Crashed 37% in January at Motley Fool
08:00AM  Growth, Factors at Play - Analyst Notes on General Electric, Dow Chemical, Bristol-Myers Squibb and Eli Lilly Accesswire
Feb-03-16 10:00AM  Bristol-Myers Squibb to Take Part in Leerink Swann Global Healthcare Conference Business Wire
09:12AM  Merck gives cautious 2016 outlook as sales of top medicines lag
Feb-02-16 01:44PM  Pfizer earnings fall but tops Street 4Q forecasts
10:03AM  Bristol-Myers Squibb Co. Earnings Analysis: Q4, 2015 By the Numbers
Feb-01-16 11:16AM  Will 2016 Be Merck & Co. Inc.'s Best Year Yet? at Motley Fool
09:10AM  Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung and Skin Cancer Screening, Care More Accessible in High-Risk U.S. Communities at noodls
09:00AM  Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung and Skin Cancer Screening, Care More Accessible in High-Risk U.S. Communities Business Wire
08:00AM  Technical Pointers on Drug Manufacturers - Major Stocks -- Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and AstraZeneca Accesswire
07:30AM  Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan at noodls
07:10AM  Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan at noodls
06:55AM  Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan Business Wire
06:01AM  Adversity Creates Opportunity
12:04AM  What Does Novartis Expect from Pharmaceuticals?
Jan-29-16 07:04PM  How Much Is Teva Spending on Research and Development?
06:52PM  Bristol-Myers' Daklinza-Sovaldi Label Expanded in the EU
04:58PM  What Will Cure Bristol-Myers Squibb?
11:28AM  With Merck Approval, Hepatitis-C Price War Back On at Barrons.com
07:48AM  Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion for Investigational Antibody, Empliciti (elotuzumab), for the Treatment of Multiple Myeloma in Patients Who Have Received at Least One Prior Therapy Business Wire
02:26AM  Edited Transcript of BMY earnings conference call or presentation 28-Jan-16 3:30pm GMT
Jan-28-16 07:32PM  FDA OKs Merck hepatitis C drug, adding to patient choices
04:40PM  Bristol-Myers set to lead earnings parade in 2016, beyond Reuters
01:22PM  [$$] Bristol-Myers Revenue Rises 1% at The Wall Street Journal
01:09PM  European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV at noodls
12:41PM  European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV Business Wire
12:35PM  Like big pharma, biotech is toxic: Trader
12:20PM  Vetr Top Raters Upgrade Bristol-Myers Squibb, Over 80% Bullish
11:57AM  Bristol-Myers Beats Q4 Estimates As Opdivo Keeps Delivering
10:53AM  Pharma, biotech stocks take a hit
10:12AM  Bristol-Myers Beats on Q4 Earnings, Provides 2016 Guidance
08:40AM  Short Sellers Become More Selective on Major Pharma at 24/7 Wall St.
08:16AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
08:13AM  Bristol-Myers (BMY) Beats on Q4 Earnings and Revenues
08:02AM  Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results at noodls
07:58AM  UPDATE 1-Bristol-Myers forecasts 2016 profit above Wall Street estimates
07:54AM  Bristol Myers Ticks Higher Following Q4 Beat, Encouraging Guidance
07:53AM  Bristol-Myers forecasts 2016 profit above Wall Street estimates
07:32AM  CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early at noodls
07:07AM  Q4 2015 Bristol-Myers Squibb Co Earnings Release - Before Market Open
07:00AM  Bristol-Myers Beats Estimates on Key Cancer Drugs Like Opdivo at Bloomberg
06:59AM  CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early Business Wire
06:59AM  Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results Business Wire
Jan-27-16 09:22PM  Bristol-Myers Squibb's Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status (197KB) at noodls
04:06PM  Bristol-Myers Squibb (BMY) Closed Down as Analysts Expect Earnings Decline at TheStreet
08:22AM  Why Bristol-Myers Squibb (BMY) Might Surprise This Earnings Season
Jan-26-16 03:19PM  Bristol-Myers' Earnings Forecasts a Healthy Dose of Growth at Investopedia
10:15AM  Genocea to study drugs that can combine with Opdivo, Keytruda at bizjournals.com
08:05AM  Does Marketing Have Too Much Control In Big Pharma Clinical Trials? at Forbes
07:20AM  GSKs 4Q15 Earnings: Will Pharmaceuticals Grow?
Jan-25-16 05:13PM  Celgene Reveals Data on Second-Line Abraxane-Gemzar
03:00PM  Will Bristol-Myers (BMY) Beat Q4 Earnings Expectations?
02:55PM  Bristol-Myers' Opdivo/Yervoy Combination Expanded in U.S.
11:43AM  JNJ Kicks Off Health Care EarningsWhat About Deals, Buybacks?
10:38AM  Earnings Outlook: JNJ Tends to Beat the Street, Can it Maintain Trend? at Forbes
10:25AM  Stock Marquee Crowded With Oil, Apple, And The Fed
06:59AM  REPEAT/ Bristol-Myers Squibbs Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1 Business Wire
06:20AM  Reasons to Expect Strong Earnings From Bristol-Myers at TheStreet
05:30AM  Draghi and a Counter Trend Rally in Oil Rescue the Markets
Jan-23-16 06:36PM  Bristol-Myers Squibbs Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1 Business Wire
Jan-22-16 10:07AM  Bristol Myers-Squibb (BMY) Stock Spikes, Analysts: Well Positioned to Generate Meaningful Growth at TheStreet
08:16AM  Analysts' Actions -- Alaska Air, Avon, Bristol-Myers, Goldman Sachs and More
06:35AM  Bristol-Myers upgraded by Berenberg
12:32AM  [$$] NHS approves £5,700-a-month skin cancer drug at Financial Times
Jan-21-16 07:01PM  Bristol-Myers Wins U.K. Nod for Melanoma Drug Despite Cost at Bloomberg
07:01PM  Bristol-Myers' Opdivo Gets Nod for Melanoma From U.K. Regulator
11:19AM  [$$] Five Pharma Picks for Another Volatile Year at Barrons.com
Jan-20-16 09:32AM  U.S. and Europe could be biggest winners from Chinas slower growth
Jan-19-16 02:44PM  Stocks Slide as Crude Oil Struggles to Hold $28 at TheStreet
08:06AM  AbbVie Is Expected to Strengthen Its Position in Virology in 4Q15
05:47AM  Perceptions vs Reality: Fear vs Reason
05:30AM  Perception vs Reality and Emotion vs. Reason
Jan-18-16 09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Biogen, Cytokinetics and Bristol-Myers Squibb
Jan-15-16 11:56AM  Bristol-Myers Squibb: A New Chapter, and the Beginning of Sustained Growth at Motley Fool
10:10AM  Stock Market News for January 15, 2016
Jan-14-16 06:50PM  [$$] Oversold Novartis: Juicy Yield, $9 Billion Pipeline at Barrons.com
Jan-13-16 09:15AM  Major Pharma Short Sellers Increase Bets at 24/7 Wall St.
Jan-12-16 12:22PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:01AM  Five 2016 winners: strategist
09:51AM  3 Things You Absolutely Must Know About Merck at Motley Fool
Jan-11-16 05:00PM  4 stocks to buy amidst a $32 billion biotech merger
10:10AM  Bristol-Myers (BMY) Collaborates with Dual Therapeutics
08:00AM  SomaLogic Completes Agreement With Bristol-Myers Squibb for Expanded Access to SOMAmer(R) Reagents Marketwired
06:31AM  The Demise of the U.S.Economy and Equity Markets are Greatly Exaggerated
05:30AM  The Demise of the U.S. Economy and Equity Markets Are Greatly Exaggerated
Jan-10-16 09:12AM  This Common Dietary Ingredient May Increase Breast Cancer and Lung Metastasis Risk at Motley Fool
Jan-09-16 12:01AM  [$$] 4 Who Beat the Market at Barrons.com
Jan-08-16 08:06AM  Mercks 4Q15 Earnings: Expected Growth Contributors
08:00AM  Dual Therapeutics Announces Oncology Strategic Collaboration With Bristol-Myers Squibb Marketwired
Jan-07-16 07:20AM  Why Portola Pharmaceuticals Shares Jumped 82% in 2015 at Motley Fool
Jan-05-16 01:18PM  Lilly Guidance Misses Estimates On Lower Sales at Investor's Business Daily
01:11PM  Bristol-Myers Squibb Co. Value Analysis (NYSE:BMY) : January 5, 2016
11:20AM  Closing Out The Year
11:07AM  2016: Review of Our Core Beliefs
10:00AM  Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference Business Wire
08:11AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : January 5, 2016
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company's products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Paliwal Dinesh CDirectorFeb 01Option Exercise0.003,25703,257Feb 03 06:28 PM
ANDREOTTI LAMBERTODirectorJan 05Sale68.1911,600791,028310,424Jan 06 04:40 PM
ANDREOTTI LAMBERTODirectorJan 04Sale66.9311,600776,332322,024Jan 06 04:40 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00950053,012Jan 05 06:21 PM
ANDREOTTI LAMBERTODirectorDec 15Sale70.0511,600812,580332,852Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorDec 14Sale68.0011,600788,843344,452Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorNov 20Sale67.7611,600786,016501,052Nov 23 04:41 PM
ANDREOTTI LAMBERTODirectorNov 19Sale67.0211,600777,470512,652Nov 23 04:41 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000163,957Nov 03 03:45 PM
Elicker John ESVP Pub Affairs & Inv RelationNov 01Option Exercise0.00496052,286Nov 03 03:45 PM
ANDREOTTI LAMBERTODirectorOct 06Sale59.7311,600692,904524,252Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorOct 05Sale61.9911,600719,027535,852Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorSep 03Sale59.5711,600691,032546,874Sep 03 06:34 PM
ANDREOTTI LAMBERTODirectorSep 02Sale59.2211,600687,005558,474Sep 03 06:34 PM
Blin EmmanuelSVP, Head of CommercializationJul 02Option Exercise0.009510953Jul 07 05:13 PM
Gordon MurdoSVP, Head of Worldwide MarketsJul 01Option Exercise0.002,33502,540Jul 06 07:17 PM
Caldarella Joseph CSVP & ControllerJun 04Sale65.7116,9721,115,22959,284Jun 08 04:17 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,55409,047Apr 03 03:39 PM
Cuss Francis MEVP & CSOMar 16Option Exercise25.52114,0102,909,160380,699Mar 17 05:54 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 16Sale67.087,000469,56022,218Mar 16 07:02 PM
Cuss Francis MEVP & CSOMar 16Sale67.81114,6667,775,501266,033Mar 17 05:54 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 13Sale66.6759139,40231,015Mar 16 07:01 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 13Sale66.795,000333,97229,218Mar 16 07:02 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.002,068042,368Mar 12 06:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.005,287035,218Mar 12 06:54 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.003,271052,348Mar 12 06:54 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.008,0190269,160Mar 12 06:54 PM
Caforio GiovanniChief Operating OfficerMar 10Option Exercise0.0010,579071,322Mar 12 06:54 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.001,788050,485Mar 12 06:55 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.005,212058,799Mar 12 06:55 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.002,977076,835Mar 12 06:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0013,2390184,290Mar 12 06:55 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0048,8500411,731Mar 12 06:56 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.009,9970307,535Mar 12 06:53 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.004,54608,057Mar 12 06:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Sale65.8410,343680,94231,606Mar 12 06:53 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043059,141Mar 10 04:53 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931074,668Mar 10 04:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043040,624Mar 10 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400374,863Mar 10 04:51 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528030,053Mar 10 04:52 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724048,631Mar 10 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390054,339Mar 10 04:53 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0090261,937Mar 10 04:54 PM
Caforio GiovanniChief Operating OfficerMar 06Option Exercise0.002,889061,986Mar 10 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230171,251Mar 10 04:52 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 06Option Exercise0.005,5730298,970Mar 10 04:52 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Sale66.2410,468693,45249,031Mar 10 04:53 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.001,033044,363Mar 04 05:14 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 02Option Exercise0.009,7470108,016Mar 04 05:14 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.003,7030245,358Mar 04 05:14 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.003,182040,705Mar 04 05:14 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.001,360051,827Mar 04 05:12 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.002,475064,025Mar 04 05:13 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.001,174035,654Mar 04 05:13 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.001,494046,893Mar 04 05:13 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.0033,5310416,594Mar 04 05:13 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.008,250060,609Mar 04 09:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.008,249043,860Mar 04 09:38 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 02Option Exercise0.0019,995034,176Mar 04 09:38 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 02Option Exercise0.0044,0840316,255Mar 04 09:39 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.0022,851070,125Mar 04 09:37 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.0023,8030270,105Mar 04 09:37 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.0018,907060,423Mar 04 09:37 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.005,725050,278Mar 04 09:37 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.0015,271079,730Mar 04 09:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.00231,2800643,964Mar 04 09:36 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Option Exercise25.4515,000381,750275,656Feb 18 05:32 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Sale60.3911,746709,282263,910Feb 18 05:32 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 12Sale59.263,880229,93334,480Feb 13 04:38 PM